Genentech, a member of the Roche Group, announced that the Phase III ALINA study evaluating Alecensa®, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival at a prespecified interim analysis.
Genentech, a member of the Roche Group, announced that the Phase III ALINA study evaluating Alecensa®, compared with platinum-based chemotherapy, met its primary endpoint of disease-free survival at a prespecified interim analysis.